Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kJ/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prolyl hydroxylase EGLN3 (Homo sapiens (Human)) | BDBM107703 (US10889546, US2007/0299086 Table 2.4 | US11426393,...) | Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 83 | n/a | n/a | n/a | n/a | n/a | n/a |
Akebia Therapeutics, Inc. US Patent | Assay Description The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T... | US Patent US8598210 (2013) BindingDB Entry DOI: 10.7270/Q2M04428 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Egl nine homolog 1 (Homo sapiens (Human)) | BDBM107702 (US8598210, Table XV, 8 | US8722895, 8: {[5-(4-Cyan...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 99 | n/a | n/a | n/a | n/a | n/a | n/a |
Akebia Therapeutics, Inc. US Patent | Assay Description The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T... | US Patent US8598210 (2013) BindingDB Entry DOI: 10.7270/Q2M04428 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Prolyl hydroxylase EGLN3 (Homo sapiens (Human)) | BDBM107698 (US11426393, Compound Table XV.4 | US8598210, Table...) | Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 180 | n/a | n/a | n/a | n/a | n/a | n/a |
Akebia Therapeutics, Inc. US Patent | Assay Description The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T... | US Patent US8598210 (2013) BindingDB Entry DOI: 10.7270/Q2M04428 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Egl nine homolog 1 (Homo sapiens (Human)) | BDBM107714 (US8598210, Table XV, 20 | US8722895, 20: {[5-(3-Cy...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 190 | n/a | n/a | n/a | n/a | n/a | n/a |
Akebia Therapeutics, Inc. US Patent | Assay Description The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T... | US Patent US8598210 (2013) BindingDB Entry DOI: 10.7270/Q2M04428 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Egl nine homolog 1 (Homo sapiens (Human)) | BDBM107703 (US10889546, US2007/0299086 Table 2.4 | US11426393,...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 240 | n/a | n/a | n/a | n/a | n/a | n/a |
Akebia Therapeutics, Inc. US Patent | Assay Description The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T... | US Patent US8598210 (2013) BindingDB Entry DOI: 10.7270/Q2M04428 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Egl nine homolog 1 (Homo sapiens (Human)) | BDBM107717 (US11426393, Compound Table XV.23 | US8598210, Tabl...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 300 | n/a | n/a | n/a | n/a | n/a | n/a |
Akebia Therapeutics, Inc. US Patent | Assay Description The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T... | US Patent US8598210 (2013) BindingDB Entry DOI: 10.7270/Q2M04428 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Egl nine homolog 1 (Homo sapiens (Human)) | BDBM107708 (US11426393, Compound Table XV.14 | US8598210, Tabl...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 300 | n/a | n/a | n/a | n/a | n/a | n/a |
Akebia Therapeutics, Inc. US Patent | Assay Description The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T... | US Patent US8598210 (2013) BindingDB Entry DOI: 10.7270/Q2M04428 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Prolyl hydroxylase EGLN3 (Homo sapiens (Human)) | BDBM107706 (US11426393, Compound Table XV.12 | US8598210, Tabl...) | Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 390 | n/a | n/a | n/a | n/a | n/a | n/a |
Akebia Therapeutics, Inc. US Patent | Assay Description The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T... | US Patent US8598210 (2013) BindingDB Entry DOI: 10.7270/Q2M04428 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Prolyl hydroxylase EGLN3 (Homo sapiens (Human)) | BDBM107704 (US11426393, Compound Table XV.11 | US8598210, 119 ...) | Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | Purchase MCE PC cid PC sid PDB UniChem Similars | US Patent | n/a | n/a | 390 | n/a | n/a | n/a | n/a | n/a | n/a |
Akebia Therapeutics, Inc. US Patent | Assay Description The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T... | US Patent US8598210 (2013) BindingDB Entry DOI: 10.7270/Q2M04428 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Egl nine homolog 1 (Homo sapiens (Human)) | BDBM107718 (US8598210, Table XV, 24 | US8722895, 24: ({3-Hydro...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 400 | n/a | n/a | n/a | n/a | n/a | n/a |
Akebia Therapeutics, Inc. US Patent | Assay Description The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T... | US Patent US8598210 (2013) BindingDB Entry DOI: 10.7270/Q2M04428 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Egl nine homolog 1 (Homo sapiens (Human)) | BDBM107704 (US11426393, Compound Table XV.11 | US8598210, 119 ...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | Purchase MCE PC cid PC sid PDB UniChem Similars | PDB US Patent | n/a | n/a | 410 | n/a | n/a | n/a | n/a | n/a | n/a |
Akebia Therapeutics, Inc. US Patent | Assay Description The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T... | US Patent US8598210 (2013) BindingDB Entry DOI: 10.7270/Q2M04428 | |||||||||||
More data for this Ligand-Target Pair | 3D Structure (crystal) | ||||||||||||
Egl nine homolog 1 (Homo sapiens (Human)) | BDBM107707 (US11426393, Compound Table XV.13 | US8598210, Tabl...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 440 | n/a | n/a | n/a | n/a | n/a | n/a |
Akebia Therapeutics, Inc. US Patent | Assay Description The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T... | US Patent US8598210 (2013) BindingDB Entry DOI: 10.7270/Q2M04428 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Prolyl hydroxylase EGLN3 (Homo sapiens (Human)) | BDBM107702 (US8598210, Table XV, 8 | US8722895, 8: {[5-(4-Cyan...) | Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 560 | n/a | n/a | n/a | n/a | n/a | n/a |
Akebia Therapeutics, Inc. US Patent | Assay Description The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T... | US Patent US8598210 (2013) BindingDB Entry DOI: 10.7270/Q2M04428 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Egl nine homolog 1 (Homo sapiens (Human)) | BDBM107698 (US11426393, Compound Table XV.4 | US8598210, Table...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 650 | n/a | n/a | n/a | n/a | n/a | n/a |
Akebia Therapeutics, Inc. US Patent | Assay Description The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T... | US Patent US8598210 (2013) BindingDB Entry DOI: 10.7270/Q2M04428 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Egl nine homolog 1 (Homo sapiens (Human)) | BDBM107706 (US11426393, Compound Table XV.12 | US8598210, Tabl...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 1.10E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Akebia Therapeutics, Inc. US Patent | Assay Description The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T... | US Patent US8598210 (2013) BindingDB Entry DOI: 10.7270/Q2M04428 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Egl nine homolog 1 (Homo sapiens (Human)) | BDBM107704 (US11426393, Compound Table XV.11 | US8598210, 119 ...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | Purchase MCE PC cid PC sid PDB UniChem Similars | PDB US Patent | n/a | n/a | 1.10E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Akebia Therapeutics, Inc. US Patent | Assay Description The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T... | US Patent US8598210 (2013) BindingDB Entry DOI: 10.7270/Q2M04428 | |||||||||||
More data for this Ligand-Target Pair | 3D Structure (crystal) | ||||||||||||
Egl nine homolog 1 (Homo sapiens (Human)) | BDBM107711 (US11426393, Compound Table XV.17 | US8598210, Tabl...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 1.20E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Akebia Therapeutics, Inc. US Patent | Assay Description The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T... | US Patent US8598210 (2013) BindingDB Entry DOI: 10.7270/Q2M04428 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Prolyl hydroxylase EGLN3 (Homo sapiens (Human)) | BDBM107711 (US11426393, Compound Table XV.17 | US8598210, Tabl...) | Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 1.30E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Akebia Therapeutics, Inc. US Patent | Assay Description The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T... | US Patent US8598210 (2013) BindingDB Entry DOI: 10.7270/Q2M04428 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Egl nine homolog 1 (Homo sapiens (Human)) | BDBM107709 (US11426393, Compound Table XV.15 | US8598210, Tabl...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 1.60E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Akebia Therapeutics, Inc. US Patent | Assay Description The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T... | US Patent US8598210 (2013) BindingDB Entry DOI: 10.7270/Q2M04428 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Egl nine homolog 1 (Homo sapiens (Human)) | BDBM107716 (US11426393, Compound Table XV.22 | US8598210, Tabl...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 2.50E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Akebia Therapeutics, Inc. US Patent | Assay Description The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T... | US Patent US8598210 (2013) BindingDB Entry DOI: 10.7270/Q2M04428 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Egl nine homolog 1 (Homo sapiens (Human)) | BDBM107710 (US11426393, Compound Table XV.16 | US8598210, Tabl...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 2.50E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Akebia Therapeutics, Inc. US Patent | Assay Description The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T... | US Patent US8598210 (2013) BindingDB Entry DOI: 10.7270/Q2M04428 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Egl nine homolog 1 (Homo sapiens (Human)) | BDBM107713 (US8598210, Table XV, 19 | US8722895, 19: ({3-Hydro...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 2.60E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Akebia Therapeutics, Inc. US Patent | Assay Description The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T... | US Patent US8598210 (2013) BindingDB Entry DOI: 10.7270/Q2M04428 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Egl nine homolog 1 (Homo sapiens (Human)) | BDBM107695 (US11426393, Compound Table XV.1 | US8598210, Table...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 2.80E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Akebia Therapeutics, Inc. US Patent | Assay Description The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T... | US Patent US8598210 (2013) BindingDB Entry DOI: 10.7270/Q2M04428 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Egl nine homolog 1 (Homo sapiens (Human)) | BDBM107696 (US11426393, Compound Table XV.2 | US8598210, Table...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 3.70E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Akebia Therapeutics, Inc. US Patent | Assay Description The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T... | US Patent US8598210 (2013) BindingDB Entry DOI: 10.7270/Q2M04428 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Egl nine homolog 1 (Homo sapiens (Human)) | BDBM107700 (US11426393, Compound Table XV.6 | US8598210, Table...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 4.10E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Akebia Therapeutics, Inc. US Patent | Assay Description The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T... | US Patent US8598210 (2013) BindingDB Entry DOI: 10.7270/Q2M04428 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Egl nine homolog 1 (Homo sapiens (Human)) | BDBM107712 (US8598210, Table XV, 18 | US8722895, 18: {[5-(3-Cy...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 5.10E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Akebia Therapeutics, Inc. US Patent | Assay Description The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T... | US Patent US8598210 (2013) BindingDB Entry DOI: 10.7270/Q2M04428 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Egl nine homolog 1 (Homo sapiens (Human)) | BDBM107697 (US8598210, Table XV, 3 | US8722895, 3: {[5-(4-Cyan...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 5.80E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Akebia Therapeutics, Inc. US Patent | Assay Description The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T... | US Patent US8598210 (2013) BindingDB Entry DOI: 10.7270/Q2M04428 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Egl nine homolog 1 (Homo sapiens (Human)) | BDBM107701 (US11426393, Compound Table XV.7 | US8598210, Table...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 6.80E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Akebia Therapeutics, Inc. US Patent | Assay Description The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T... | US Patent US8598210 (2013) BindingDB Entry DOI: 10.7270/Q2M04428 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Egl nine homolog 1 (Homo sapiens (Human)) | BDBM107719 (US11426393, Compound Table XV.25 | US8598210, Tabl...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 9.20E+3 | n/a | n/a | n/a | n/a | n/a | n/a |
Akebia Therapeutics, Inc. US Patent | Assay Description The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T... | US Patent US8598210 (2013) BindingDB Entry DOI: 10.7270/Q2M04428 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Egl nine homolog 1 (Homo sapiens (Human)) | BDBM107715 (US11426393, Compound Table XV.21 | US8598210, Tabl...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 1.12E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Akebia Therapeutics, Inc. US Patent | Assay Description The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T... | US Patent US8598210 (2013) BindingDB Entry DOI: 10.7270/Q2M04428 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Egl nine homolog 1 (Homo sapiens (Human)) | BDBM107699 (US11426393, Compound Table XV.5 | US8598210, Table...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 2.00E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Akebia Therapeutics, Inc. US Patent | Assay Description The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T... | US Patent US8598210 (2013) BindingDB Entry DOI: 10.7270/Q2M04428 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Prolyl hydroxylase EGLN3 (Homo sapiens (Human)) | BDBM107695 (US11426393, Compound Table XV.1 | US8598210, Table...) | Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 2.14E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Akebia Therapeutics, Inc. US Patent | Assay Description The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T... | US Patent US8598210 (2013) BindingDB Entry DOI: 10.7270/Q2M04428 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Prolyl hydroxylase EGLN3 (Homo sapiens (Human)) | BDBM107701 (US11426393, Compound Table XV.7 | US8598210, Table...) | Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 3.75E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Akebia Therapeutics, Inc. US Patent | Assay Description The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T... | US Patent US8598210 (2013) BindingDB Entry DOI: 10.7270/Q2M04428 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Prolyl hydroxylase EGLN3 (Homo sapiens (Human)) | BDBM107700 (US11426393, Compound Table XV.6 | US8598210, Table...) | Reactome pathway KEGG UniProtKB/SwissProt DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 5.23E+4 | n/a | n/a | n/a | n/a | n/a | n/a |
Akebia Therapeutics, Inc. US Patent | Assay Description The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T... | US Patent US8598210 (2013) BindingDB Entry DOI: 10.7270/Q2M04428 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Vascular endothelial growth factor A (Homo sapiens (Human)) | BDBM107708 (US11426393, Compound Table XV.14 | US8598210, Tabl...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | n/a | n/a | >1.00E+5 | n/a | n/a | n/a | n/a |
Akebia Therapeutics, Inc. US Patent | Assay Description HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight... | US Patent US8598210 (2013) BindingDB Entry DOI: 10.7270/Q2M04428 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Vascular endothelial growth factor A (Homo sapiens (Human)) | BDBM107700 (US11426393, Compound Table XV.6 | US8598210, Table...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | n/a | n/a | 8.20E+3 | n/a | n/a | n/a | n/a |
Akebia Therapeutics, Inc. US Patent | Assay Description HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight... | US Patent US8598210 (2013) BindingDB Entry DOI: 10.7270/Q2M04428 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Vascular endothelial growth factor A (Homo sapiens (Human)) | BDBM107697 (US8598210, Table XV, 3 | US8722895, 3: {[5-(4-Cyan...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | n/a | n/a | >1.00E+5 | n/a | n/a | n/a | n/a |
Akebia Therapeutics, Inc. US Patent | Assay Description HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight... | US Patent US8598210 (2013) BindingDB Entry DOI: 10.7270/Q2M04428 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Vascular endothelial growth factor A (Homo sapiens (Human)) | BDBM107716 (US11426393, Compound Table XV.22 | US8598210, Tabl...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | n/a | n/a | >1.00E+5 | n/a | n/a | n/a | n/a |
Akebia Therapeutics, Inc. US Patent | Assay Description HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight... | US Patent US8598210 (2013) BindingDB Entry DOI: 10.7270/Q2M04428 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Vascular endothelial growth factor A (Homo sapiens (Human)) | BDBM107714 (US8598210, Table XV, 20 | US8722895, 20: {[5-(3-Cy...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | n/a | n/a | >1.00E+5 | n/a | n/a | n/a | n/a |
Akebia Therapeutics, Inc. US Patent | Assay Description HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight... | US Patent US8598210 (2013) BindingDB Entry DOI: 10.7270/Q2M04428 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Vascular endothelial growth factor A (Homo sapiens (Human)) | BDBM107696 (US11426393, Compound Table XV.2 | US8598210, Table...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | n/a | n/a | >1.00E+5 | n/a | n/a | n/a | n/a |
Akebia Therapeutics, Inc. US Patent | Assay Description HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight... | US Patent US8598210 (2013) BindingDB Entry DOI: 10.7270/Q2M04428 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Vascular endothelial growth factor A (Homo sapiens (Human)) | BDBM107710 (US11426393, Compound Table XV.16 | US8598210, Tabl...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | n/a | n/a | 3.30E+3 | n/a | n/a | n/a | n/a |
Akebia Therapeutics, Inc. US Patent | Assay Description HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight... | US Patent US8598210 (2013) BindingDB Entry DOI: 10.7270/Q2M04428 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Vascular endothelial growth factor A (Homo sapiens (Human)) | BDBM107701 (US11426393, Compound Table XV.7 | US8598210, Table...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | n/a | n/a | 7.70E+3 | n/a | n/a | n/a | n/a |
Akebia Therapeutics, Inc. US Patent | Assay Description HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight... | US Patent US8598210 (2013) BindingDB Entry DOI: 10.7270/Q2M04428 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Vascular endothelial growth factor A (Homo sapiens (Human)) | BDBM107702 (US8598210, Table XV, 8 | US8722895, 8: {[5-(4-Cyan...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | n/a | n/a | 4.30E+3 | n/a | n/a | n/a | n/a |
Akebia Therapeutics, Inc. US Patent | Assay Description HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight... | US Patent US8598210 (2013) BindingDB Entry DOI: 10.7270/Q2M04428 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Vascular endothelial growth factor A (Homo sapiens (Human)) | BDBM107698 (US11426393, Compound Table XV.4 | US8598210, Table...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | n/a | n/a | 4.21E+4 | n/a | n/a | n/a | n/a |
Akebia Therapeutics, Inc. US Patent | Assay Description HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight... | US Patent US8598210 (2013) BindingDB Entry DOI: 10.7270/Q2M04428 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Vascular endothelial growth factor A (Homo sapiens (Human)) | BDBM107695 (US11426393, Compound Table XV.1 | US8598210, Table...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | n/a | n/a | 9.90E+3 | n/a | n/a | n/a | n/a |
Akebia Therapeutics, Inc. US Patent | Assay Description HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight... | US Patent US8598210 (2013) BindingDB Entry DOI: 10.7270/Q2M04428 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Vascular endothelial growth factor A (Homo sapiens (Human)) | BDBM107718 (US8598210, Table XV, 24 | US8722895, 24: ({3-Hydro...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | n/a | n/a | >1.00E+5 | n/a | n/a | n/a | n/a |
Akebia Therapeutics, Inc. US Patent | Assay Description HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight... | US Patent US8598210 (2013) BindingDB Entry DOI: 10.7270/Q2M04428 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Vascular endothelial growth factor A (Homo sapiens (Human)) | BDBM107717 (US11426393, Compound Table XV.23 | US8598210, Tabl...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | n/a | n/a | >1.00E+5 | n/a | n/a | n/a | n/a |
Akebia Therapeutics, Inc. US Patent | Assay Description HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight... | US Patent US8598210 (2013) BindingDB Entry DOI: 10.7270/Q2M04428 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Vascular endothelial growth factor A (Homo sapiens (Human)) | BDBM107712 (US8598210, Table XV, 18 | US8722895, 18: {[5-(3-Cy...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | n/a | n/a | >1.00E+5 | n/a | n/a | n/a | n/a |
Akebia Therapeutics, Inc. US Patent | Assay Description HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight... | US Patent US8598210 (2013) BindingDB Entry DOI: 10.7270/Q2M04428 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Vascular endothelial growth factor A (Homo sapiens (Human)) | BDBM107707 (US11426393, Compound Table XV.13 | US8598210, Tabl...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | n/a | n/a | 1.50E+4 | n/a | n/a | n/a | n/a |
Akebia Therapeutics, Inc. US Patent | Assay Description HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight... | US Patent US8598210 (2013) BindingDB Entry DOI: 10.7270/Q2M04428 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Vascular endothelial growth factor A (Homo sapiens (Human)) | BDBM107699 (US11426393, Compound Table XV.5 | US8598210, Table...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | n/a | n/a | >1.00E+5 | n/a | n/a | n/a | n/a |
Akebia Therapeutics, Inc. US Patent | Assay Description HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight... | US Patent US8598210 (2013) BindingDB Entry DOI: 10.7270/Q2M04428 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Vascular endothelial growth factor A (Homo sapiens (Human)) | BDBM107713 (US8598210, Table XV, 19 | US8722895, 19: ({3-Hydro...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | n/a | n/a | >1.00E+5 | n/a | n/a | n/a | n/a |
Akebia Therapeutics, Inc. US Patent | Assay Description HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight... | US Patent US8598210 (2013) BindingDB Entry DOI: 10.7270/Q2M04428 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Vascular endothelial growth factor A (Homo sapiens (Human)) | BDBM107711 (US11426393, Compound Table XV.17 | US8598210, Tabl...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | n/a | n/a | 1.40E+3 | n/a | n/a | n/a | n/a |
Akebia Therapeutics, Inc. US Patent | Assay Description HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight... | US Patent US8598210 (2013) BindingDB Entry DOI: 10.7270/Q2M04428 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Vascular endothelial growth factor A (Homo sapiens (Human)) | BDBM107709 (US11426393, Compound Table XV.15 | US8598210, Tabl...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | n/a | n/a | >1.00E+5 | n/a | n/a | n/a | n/a |
Akebia Therapeutics, Inc. US Patent | Assay Description HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight... | US Patent US8598210 (2013) BindingDB Entry DOI: 10.7270/Q2M04428 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Vascular endothelial growth factor A (Homo sapiens (Human)) | BDBM107715 (US11426393, Compound Table XV.21 | US8598210, Tabl...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | n/a | n/a | 5.01E+4 | n/a | n/a | n/a | n/a |
Akebia Therapeutics, Inc. US Patent | Assay Description HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight... | US Patent US8598210 (2013) BindingDB Entry DOI: 10.7270/Q2M04428 | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Vascular endothelial growth factor A (Homo sapiens (Human)) | BDBM107704 (US11426393, Compound Table XV.11 | US8598210, 119 ...) | PDB MMDB Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet | Purchase MCE PC cid PC sid PDB UniChem Similars | US Patent | n/a | n/a | n/a | n/a | 7.60E+3 | n/a | n/a | n/a | n/a |
Akebia Therapeutics, Inc. US Patent | Assay Description HEK293 cells are seeded in 96-well poly-lysine coated plates at 20,000 cells per well in DMEM (10% FBS, 1% NEAA, 0.1% glutamine). Following overnight... | US Patent US8598210 (2013) BindingDB Entry DOI: 10.7270/Q2M04428 | |||||||||||
More data for this Ligand-Target Pair |